Key points:
1. Checkmate 816 vs. Checkmate 77T: We explored an exploratory analysis comparing neoadjuvant chemoimmunotherapy (Checkmate 816) with the sandwich approach of chemoimmunotherapy followed by surgery and post-operative immunotherapy (Checkmate 770). Dr. Lopes emphasized the ongoing uncertainty regarding the true benefit of post-operative immunotherapy, particularly for patients with a complete pathologic response.
2. SKIPPirr Study: This study aimed to reduce infusion-related reactions associated with amivantamab. Dr. Lopes shared promising results showing that a prophylactic regimen of dexamethasone significantly decreased the infusion reaction rate from 70% to 22.5%. This is a crucial step as we anticipate the approval of a subcutaneous formulation of amivantamab, which is expected to further reduce these reactions.
3. HARMONi-2 Study: We discussed a novel PD-1 and VEGF bispecific antibody, evonucimab, which is being compared to pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Dr. Lopes highlighted the potential of this combination therapy, although he noted the need for further global studies to validate its efficacy.
4. TROPION-Lung01: Lastly, we reviewed the data from the TROPION- Lung01 study, which compared the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) to docetaxel in patients with metastatic NSCLC. While the overall survival results were underwhelming, there were indications of benefit in specific patient populations, particularly those with non-squamous histology.
In this episode of the Oncology Brothers podcast, we had the pleasure of discussing key highlights from the World Conference on Lung Cancer 2024 with Dr. Gilberto Lopes, Chief of Medical Oncology at the Sylvester Comprehensive Cancer Center.
We focused on four significant studies that can enhance our current standard of care in community settings.
Throughout the episode, we emphasized the importance of ongoing research and the need for longer follow-up data to better guide treatment decisions in lung cancer. We appreciate Dr. Lopes for sharing his insights and look forward to seeing how these studies will shape our practice in the future. Thank you for tuning in, and be sure to check out our other conference highlights and discussions on the current standard of care. We are the Oncology Brothers!
